TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: The six evaluable CTCL patients (#18 CD30+ ALCL, #29 MF, #38 MF, #39 MF, #17 GSS and #37 CD30+ ALCL) with a stable disease (SD) had a stable or decreased frequency of CD3+ cells.